Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
Abstract Background This study aimed to assess the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering lipid levels among chronic kidney disease (CKD) patients, including those with stages 4–5 CKD. Methods CKD patients with atherosclerotic cardiovascul...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-04347-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226557305913344 |
|---|---|
| author | Haixia Tang Xiaomin Li Fengmei Wang Hong Liu Xiaoliang Zhang Bicheng Liu Bin Wang |
| author_facet | Haixia Tang Xiaomin Li Fengmei Wang Hong Liu Xiaoliang Zhang Bicheng Liu Bin Wang |
| author_sort | Haixia Tang |
| collection | DOAJ |
| description | Abstract Background This study aimed to assess the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering lipid levels among chronic kidney disease (CKD) patients, including those with stages 4–5 CKD. Methods CKD patients with atherosclerotic cardiovascular disease treated between January 2022 and December 2022 at Zhong Da Hospital affiliated with Southeast University were enrolled in this study. Patients received either evolocumab or alirocumab for three months, either in combination with statin therapy with or without ezetimibe. Efficacy and safety measures were compared among the different groups before and after treatment. Results A total of 496 CKD patients were included in the study, comprising 263 with stages 1–2 CKD, 170 with stage 3 CKD, and 63 with stages 4–5 CKD. Among them, 301 patients were classified into the atherosclerotic cardiovascular disease (ASCVD) group, whereas 195 were classified into the very-high-risk ASCVD group. LDL-C, total cholesterol (TC), and lipoprotein (a) (Lp(a)) levels decreased significantly in all groups, including stages 4–5 CKD patients, after treatment (P < 0.05). The serum creatinine (Scr) level and estimated glomerular filtration rate (eGFR) remained stable during treatment (P > 0.05). The incidence of adverse drug events did not differ significantly among the different kidney function groups (P ≥ 0.05). Conclusions PCSK9 inhibitors can be effectively and safely utilized for lipid-lowering therapy in CKD patients, even those with stages 4–5 CKD. Clinical trial number Not applicable. |
| format | Article |
| id | doaj-art-2a64634b887e471b9d0d4b85547b4ad8 |
| institution | Kabale University |
| issn | 1471-2369 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj-art-2a64634b887e471b9d0d4b85547b4ad82025-08-24T11:13:02ZengBMCBMC Nephrology1471-23692025-08-0126111010.1186/s12882-025-04347-1Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney diseaseHaixia Tang0Xiaomin Li1Fengmei Wang2Hong Liu3Xiaoliang Zhang4Bicheng Liu5Bin Wang6Department of Nephrology, Zhongda Hospital, Southeast University School of MedicineDepartment of Pharmacy, Zhongda Hospital, Southeast University School of MedicineDepartment of Nephrology, Zhongda Hospital, Southeast University School of MedicineDepartment of Nephrology, Zhongda Hospital, Southeast University School of MedicineDepartment of Nephrology, Zhongda Hospital, Southeast University School of MedicineDepartment of Nephrology, Zhongda Hospital, Southeast University School of MedicineDepartment of Nephrology, Zhongda Hospital, Southeast University School of MedicineAbstract Background This study aimed to assess the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering lipid levels among chronic kidney disease (CKD) patients, including those with stages 4–5 CKD. Methods CKD patients with atherosclerotic cardiovascular disease treated between January 2022 and December 2022 at Zhong Da Hospital affiliated with Southeast University were enrolled in this study. Patients received either evolocumab or alirocumab for three months, either in combination with statin therapy with or without ezetimibe. Efficacy and safety measures were compared among the different groups before and after treatment. Results A total of 496 CKD patients were included in the study, comprising 263 with stages 1–2 CKD, 170 with stage 3 CKD, and 63 with stages 4–5 CKD. Among them, 301 patients were classified into the atherosclerotic cardiovascular disease (ASCVD) group, whereas 195 were classified into the very-high-risk ASCVD group. LDL-C, total cholesterol (TC), and lipoprotein (a) (Lp(a)) levels decreased significantly in all groups, including stages 4–5 CKD patients, after treatment (P < 0.05). The serum creatinine (Scr) level and estimated glomerular filtration rate (eGFR) remained stable during treatment (P > 0.05). The incidence of adverse drug events did not differ significantly among the different kidney function groups (P ≥ 0.05). Conclusions PCSK9 inhibitors can be effectively and safely utilized for lipid-lowering therapy in CKD patients, even those with stages 4–5 CKD. Clinical trial number Not applicable.https://doi.org/10.1186/s12882-025-04347-1Proprotein convertase subtilisin/Kexin type 9 inhibitorsChronic kidney diseaseRetrospective study |
| spellingShingle | Haixia Tang Xiaomin Li Fengmei Wang Hong Liu Xiaoliang Zhang Bicheng Liu Bin Wang Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease BMC Nephrology Proprotein convertase subtilisin/Kexin type 9 inhibitors Chronic kidney disease Retrospective study |
| title | Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease |
| title_full | Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease |
| title_fullStr | Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease |
| title_full_unstemmed | Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease |
| title_short | Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease |
| title_sort | efficacy and safety of pcsk9 inhibitors in patients with chronic kidney disease |
| topic | Proprotein convertase subtilisin/Kexin type 9 inhibitors Chronic kidney disease Retrospective study |
| url | https://doi.org/10.1186/s12882-025-04347-1 |
| work_keys_str_mv | AT haixiatang efficacyandsafetyofpcsk9inhibitorsinpatientswithchronickidneydisease AT xiaominli efficacyandsafetyofpcsk9inhibitorsinpatientswithchronickidneydisease AT fengmeiwang efficacyandsafetyofpcsk9inhibitorsinpatientswithchronickidneydisease AT hongliu efficacyandsafetyofpcsk9inhibitorsinpatientswithchronickidneydisease AT xiaoliangzhang efficacyandsafetyofpcsk9inhibitorsinpatientswithchronickidneydisease AT bichengliu efficacyandsafetyofpcsk9inhibitorsinpatientswithchronickidneydisease AT binwang efficacyandsafetyofpcsk9inhibitorsinpatientswithchronickidneydisease |